Gene · 2213
NIH grants2,625
NIH grants whose papers are about the gene, through NIH's grant-paper links.
561 to 580 of 2,625
Download this page as JSON| Grant | Title | FCGR2B papers | Newest fiscal year |
|---|---|---|---|
| R01AI147870 | Engineering of pan-neutralizing anti-HIV envelope antibodies | 1 | 2024 |
| R01AI148129 | Post-Initiation control of transcription in inflammatory macrophages | 1 | 2024 |
| R01AI148487 | Nuclear Receptors in B Cell Tolerance and Humoral Immune Responses | 1 | 2024 |
| R01AI148543 | Antibody therapy of MRSA colonization and infection | 1 | 2024 |
| R01AI148705 | Intrarenal B cells in acute kidney allograft rejection | 1 | 2024 |
| R01AI149431 | Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease | 1 | 2024 |
| R01AI149486 | Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta | 1 | 2024 |
| R01AI149724 | Memory T Cell Cosigning Pathways in Sepsis-Induced Immune Dysregulation | 1 | 2024 |
| R01AI150191 | The IL-33/ILC2 axis in parturition | 1 | 2024 |
| R01AI152158 | Multiplexed Antigen-Specific Antibody Fc Profiling on a Chip for Point-of-Care Diagnosis of TB in HIV-infected Children | 1 | 2024 |
| R01AI152236 | Development of vaccines targeting a tick-borne phlebovirus | 1 | 2024 |
| R01AI152535 | Role and mechanisms of the PI3K pathway in B cell tolerance | 1 | 2024 |
| R01AI155163 | Tethering lentiviral restriction to Fc-mediated antibody responses | 1 | 2024 |
| R01AI155716 | Glycoengineering of antibodies to modulate immune functions | 1 | 2024 |
| R01AR065538 | Ly6 family members in neutrophil biology | 1 | 2024 |
| R01AR074939 | Role of protein citrullination in rheumatoid arthritis | 1 | 2024 |
| R01CA189806 | Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma | 1 | 2024 |
| R01CA242020 | Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia | 1 | 2024 |
| R01CA245147 | Targeting cancer stem cells in JAK2V617F induced neoplasm | 1 | 2024 |
| R01CA246716 | Drug-Free Macromolecular Therapeutics | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2213/grants?page=29